Arginine vasopressin induces periaqueductal gray release of enkephalin and endorphin relating to pain modulation in the rat.
Previous study has proven that microinjection of arginine vasopressin (AVP) into periaqueductal gray (PAG) raises the pain threshold, in which the antinociceptive effect of AVP can be reversed by PAG pretreatment with V2 rather than V1 or opiate receptor antagonist. The present work investigated the AVP effect on endogenous opiate peptides, oxytocin (OXT) and classical neurotransmitters in the rat PAG. The results showed that AVP elevated the concentrations of leucine-enkephalin (L-Ek), methionine-enkephalin (M-Ek) and beta-endorphin (beta-Ep), but did not change the concentrations of dynorphinA(1-13) (DynA(1-13)), OXT, classical neurotransmitters including achetylcholine (Ach), choline (Ch), serotonin (5-HT), gamma-aminobutyric acid (GABA), glutamate (Glu), dopamine (DA), norepinephrine (NE) and epinephrine (E), and their metabolic products in PAG perfusion liquid. Pain stimulation increased the concentrations of AVP, L-EK, M-Ek, beta-Ep, 5-HT and 5-HIAA (5-HT metabolic product), but did not influence the concentrations of DynA(1-13), OXT, the other classical neurotransmitters and their metabolic products. PAG pretreatment with naloxone - an opiate receptor antagonist completely attenuated the pain threshold increase induced by PAG administration of AVP, but local pretreatment of OXT or classical neurotransmitter receptor antagonist did not influence the pain threshold increase induced by PAG administration of AVP. The data suggested that AVP in PAG could induce the local release of enkephalin and endorphin rather than dynophin, OXT and classical neurotransmitters to participate in pain modulation.
Yang
Jun
J
Institute for Pharmaceuticals and Medical Science, Guangdong Bangmin Pharmaceutical Co. Ltd., Jianghai Distract, Jiangmen, Guangdong, 529080 China. yj6676@yahoo.com
Yang
Yu
Y
Xu
Hong-Tao
HT
Chen
Jian-Min
JM
Liu
Wen-Yan
WY
Lin
Bao-Cheng
BC
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000494:pharmacology*; D002794:Choline / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004723:Endorphins / Q000378:metabolism*; D004743:Enkephalin, Leucine / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000378:metabolism; D004745:Enkephalins / Q000378:metabolism*; D004837:Epinephrine / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D018847:Opioid Peptides / Q000378:metabolism; D010121:Oxytocin / Q000378:metabolism; D010146:Pain / Q000378:metabolism*; D017288:Pain Threshold / Q000187:drug effects; D010487:Periaqueductal Gray / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism; D001615:beta-Endorphin / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D004723:Endorphins; D004745:Enkephalins; D018847:Opioid Peptides; D001127:Arginine Vasopressin; D012701:Serotonin; D018698:Glutamic Acid; D010121:Oxytocin; D005680:gamma-Aminobutyric Acid; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D001615:beta-Endorphin; D002794:Choline; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine